Lithium aluminum deuteride (CAS 14128-54-2; LiAlD₄; molecular weight 41.98 g mol⁻¹) is supplied as a pharmaceutical-grade deuteride-transfer reagent for active pharmaceutical ingredient synthesis. Catalogue designations that include tablet, capsule, granule, oral, or injectable presentations refer to the deuterated drug substances obtained after reduction and purification, not to direct use of the reagent in a dosage form. The compound is an off-white to gray, moisture-sensitive solid requiring inert-atmosphere handling. No harmonized pharmacopoeial monograph exists; supplier model codes such as LAD-PG-98.0 or LAD-PG-98.5 are used, with the numeric suffix indicating the minimum isotopic enrichment of 98.0 atom % D or 98.5 atom % D. Published data for a specific pharma-grade lithium aluminum deuteride configuration is limited, so release criteria should be established from supplier qualification and process validation under ICH Q7.

Because the material is a reducing agent and not a conventional API, qualification focuses on critical quality attributes that affect downstream deuterium incorporation and impurity carryover. Residual protium carriers, residual solvents, lithium and aluminum impurities, and moisture can reduce effective deuteride content and alter the isotopic purity of the final API. Incoming material is tested against supplier-validated limits and retained for batch traceability under 21 CFR 211.160 and ICH Q7.

Why Is Direct Formulation of Lithium Aluminum Deuteride in Oral and Injectable Dosage Forms Contraindicated?

Lithium aluminum deuteride is not a final API and cannot enter tablet, capsule, granule, or injectable formulations directly. The compound reacts violently with water, alcohols, and carboxylic acids; contact with aqueous gastric fluid or a Water for Injection vehicle would generate heat and hydrogen isotopes. In a manufacturing setting, this reactivity requires storage in a nitrogen-filled glovebox with oxygen below 0.5 ppm and moisture below 0.5 ppm, and transfer through PTFE or stainless-steel lines. These constraints conflict with aqueous granulation, direct compression at ambient humidity, and aseptic filling of aqueous solutions.

The final deuterated API, not LiAlD₄, enters dosage forms. For oral and injectable products, residual Li⁺, Al³⁺, and deuterated solvents are controlled in the drug substance. Direct compression and aqueous granulation are applied only after the reagent has been removed by quench, extraction, crystallization, and drying.

In a GMP synthesis for a tablet or capsule API, LiAlD₄ is metered as a solid from a loss-in-weight feeder under a nitrogen sweep or as a solution in tetrahydrofuran into a jacketed vessel. Wetted surfaces are Hastelloy C22, borosilicate glass, or PTFE to minimize metal-catalysed decomposition. The addition temperature is maintained between −10 °C and 10 °C for most carbonyl reductions; process calorimetry is used to detect accumulation. Engineering assessments of analogous LiAlH₄ reductions indicate that a delay between reagent addition and observed exotherm can occur when the first portion reacts slowly, creating an accumulation hazard. The same risk applies to LiAlD₄ because deuteride transfer is not kinetically identical to hydride transfer. No universal conversion factor can be applied across substrates.

Reaction calorimetry on LiAlD₄ reductions shows that initial heat release may be delayed by an initiation period. In a jacketed reactor, controlled addition is set so that the exotherm remains within jacket cooling capacity. For analogous LiAlH₄ systems, the main heat release is attributed to reduction and subsequent quench. The deuterated analogue is expected to exhibit a measurable but route-dependent kinetic isotope effect because the force constants of Li–D and C–D bonds differ from Li–H and C–H. Scale-up therefore requires adiabatic calorimetry screening and a worst-case accumulation test.

After quench, the product is isolated and assayed. Deuterium incorporation is measured by ²H NMR or by the decrease in ¹H NMR integration at the position of interest. A 600 MHz NMR spectrometer is commonly used for structural assignment; quantitative NMR requires a relaxation delay sufficient for the nuclei of interest. The final API is then purified by crystallization or preparative chromatography before blending or granulation.

For tablet and capsule forms, the purified deuterated API is blended in a bin blender or high-shear granulator. Blend uniformity is assessed by USP <905>. Granule production may use dry granulation or wet granulation with water-miscible binders if the final API is stable. Lubrication is performed with magnesium stearate at levels established by qualification; particle size of the final API is controlled by laser diffraction per ISO 13320:2020, and milling is carried out in a nitrogen-inerted cone mill where necessary to protect labile isotope positions. For injectable forms, the purified API is dissolved in Water for Injection, filtered through a 0.22 µm sterilizing-grade filter, and aseptically filled in an ISO 14644-1 Grade A zone.

When Tablets, Capsules, Granules, or Injections Require a Deuterated Active Intermediate

LiAlD₄ is selected when the synthetic route requires deuterium incorporation at a reducible carbon. The reagent transfers deuteride to aldehydes, ketones, carboxylic acids, esters, amides, nitriles, and epoxides. This functional-group scope is a key difference from sodium borodeuteride, which reduces aldehydes and ketones cleanly but does not reduce simple esters or amides under standard conditions. Consequently, LiAlD₄ allows introduction of carbon-bound deuterium at a carboxylic acid carbon during reduction to a primary alcohol, while NaBD₄ would not reduce the same substrate without activation.

Another difference is handling severity. LiAlD₄ requires strict aprotic conditions and controlled quenching; NaBD₄ can often be handled in alcoholic solvents with slower solvent decomposition, but the protic solvent may erode isotope enrichment through proton exchange. Deuterium gas with a palladium or platinum catalyst saturates C=C bonds and can exchange aromatic C–H positions, but it does not reduce a ketone to a deuterated alcohol. Deuterium oxide exchanges O–H, N–H, and enolizable C–H positions but produces labels that can be labile in biological systems and during analyte workup.

The following comparison summarizes practical distinctions.

The selection of deuterium source must be confirmed by a compatibility study using the actual API intermediate. Process analytical technology may include in-situ FTIR or Raman spectroscopy to track reduction when the carbonyl band is resolved. A specific LiAlD₄-mediated reduction should be verified under the intended GMP conditions because trace moisture, solvent, and mixing geometry affect rate and impurity profile. Carbon-bound deuterium introduced by LiAlD₄ is generally retained through crystallization and lyophilization, but later hydrogenation or metal-catalysed exchange can erase it.

Pharmaceutical-grade lithium aluminum deuteride release specifications are derived from risk assessment because no pharmacopoeial monograph exists. A certificate should include appearance, isotopic enrichment, chemical purity by hydride content, residual solvents, and elemental impurities. Tetrahydrofuran, a Class 2 solvent under ICH Q3C, has a permitted concentration limit of 720 ppm and a daily permitted exposure of 7.2 mg/day. Residual THF is measured by headspace gas chromatography per USP <467>. Elemental impurities are measured by ICP-MS and controlled against ICH Q3D. The absence of a direct monograph requires the user to establish acceptance criteria from batch data; a supplier certificate is not sufficient to waive incoming identity and purity testing under 21 CFR 211.160.

Hydride content may be measured by gas volumetric assay after treating the material with a controlled isopropanol-water mixture. A representative release criterion is not less than 95.0% hydride content and 98.0 atom % D isotopic enrichment, but other supplier grades may specify 99 atom % D for high-specificity APIs. Trace lithium and aluminum species are controlled because they can precipitate or complex with the final drug substance during workup. Moisture is a critical rejection parameter; containers with headspace moisture above 0.5 ppm should not be used in a validated GMP campaign without re-drying and supplier reassessment.

Batch Release Parameters and Pharmacopoeial Method Alignment

For incoming pharmaceutical-grade LiAlD₄, the following quality elements are recommended for a batch release matrix. The limits shown are typical or regulatory-derived and must be replaced by supplier-validated numbers for the actual product code and dosage form.

For oral solids, the final deuterated drug substance is sized, blended, and compressed. Disintegration testing follows USP <701>, and dissolution testing follows USP <711>. Capsule filling may use a tamping-pin or dosing-disc machine; mass uniformity is assessed by USP <905>. Granule formulations are dried to a loss-on-drying limit established by stability data, and residual water is measured by Karl Fischer titration per USP <921> Method Ia where the final API is not water-reactive. The reagent LiAlD₄ remains upstream; no residual reactive deuteride should be present in the final drug product, and absence is confirmed by a suitable method during release.

For injectable presentations, the purified deuterated API is dissolved in Water for Injection, filtered through a 0.22 µm sterilizing-grade filter, filled into depyrogenated vials, and lyophilized where stability requires. Lyophilization cycle parameters are based on thermal characterization by differential scanning calorimetry and freeze-drying microscopy. The final cake is tested for reconstitution time, residual moisture, and particulate matter per USP <788> and USP <790>. The deuterium label at carbon is not affected by lyophilization, but residual moisture in the lyophilized cake must be controlled below the stability limit established for the specific product.